Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger (Nasdaq: SDGR), a company revolutionizing therapeutics and materials discovery through physics-based computational platforms, has announced the granting of restricted stock units (RSUs) to 13 new employees. On August 14, 2024, the company awarded a total of 7,500 RSUs as part of its 2021 Inducement Equity Incentive Plan. These grants, approved by the compensation committee, serve as a material inducement for employment in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs have a four-year vesting schedule, with 25% vesting after 12 months of continuous service, followed by equal yearly installments over the subsequent three years. This move aligns with Schrödinger's strategy to attract and retain top talent in the competitive field of computational drug and materials discovery.
Schrödinger (Nasdaq: SDGR), un'azienda che sta rivoluzionando la scoperta di terapie e materiali attraverso piattaforme computazionali basate sulla fisica, ha annunciato l'assegnazione di unità di azioni riservate (RSU) a 13 nuovi dipendenti. Il 14 agosto 2024, l'azienda ha conferito un totale di 7.500 RSU come parte del suo Piano di Incentivo Azionario di Induzione 2021. Questi attribuzioni, approvate dal comitato per la compensazione, fungono da incentivo materiale per l'assunzione in conformità con la Regola di Listing Nasdaq 5635(c)(4).
Le RSU hanno un programma di vesting di quattro anni, con il 25% che matura dopo 12 mesi di servizio continuativo, seguito da rate annuali uguali nei tre anni successivi. Questa mossa è in linea con la strategia di Schrödinger di attrarre e trattenere talenti di alto livello nel competitivo campo della scoperta di farmaci e materiali computazionali.
Schrödinger (Nasdaq: SDGR), una empresa que está revolucionando el descubrimiento de terapias y materiales a través de plataformas computacionales basadas en la física, ha anunciado la concesión de unidades de acciones restringidas (RSU) a 13 nuevos empleados. El 14 de agosto de 2024, la empresa otorgó un total de 7,500 RSU como parte de su Plan de Incentivo de Equidad por Inducción de 2021. Estas otorgas, aprobadas por el comité de compensación, sirven como un incentivo material para el empleo, de acuerdo con la Regla de Listado 5635(c)(4) de Nasdaq.
Las RSU tienen un calendario de adquisición de cuatro años, con un 25% que se adquiere después de 12 meses de servicio continuo, seguido de cuotas anuales iguales durante los tres años siguientes. Este movimiento está alineado con la estrategia de Schrödinger de atraer y retener talento de primer nivel en el competitivo campo del descubrimiento de fármacos y materiales computacionales.
슈뢰딩거 (Nasdaq: SDGR)는 물리학 기반의 컴퓨터 플랫폼을 통해 치료제 및 소재 발견의 혁신을 이끌고 있는 회사로, 13명의 신입 직원에게 제한 주식 보상 단위(RSU)를 부여했다고 발표했습니다. 2024년 8월 14일, 회사는 2021 유도 주식 보상 계획의 일환으로 총 7,500 RSU를 수여했습니다. 이 부여는 보상 위원회의 승인을 받아 Nasdaq 상장 규칙 5635(c)(4)에 따른 고용 유인을 제공합니다.
RSU는 4년의 베스팅 일정을 가지며, 12개월의 연속 서비스 후 25%가 배정되고, 이후 3년 동안 동등한 연간 할당이 이루어집니다. 이 조치는 계산약물 및 소재 발견 분야에서 최우수 인재를 유치하고 유지하기 위한 슈뢰딩거의 전략과 일치합니다.
Schrödinger (Nasdaq: SDGR), une entreprise qui révolutionne la découverte de thérapies et de matériaux grâce à des plateformes computationnelles basées sur la physique, a annoncé l'attribution d'unités d'actions restreintes (RSU) à 13 nouveaux employés. Le 14 août 2024, l'entreprise a attribué un total de 7 500 RSU dans le cadre de son Plan d'Incentive en Équité d'Induction de 2021. Ces attributions, approuvées par le comité de rémunération, servent d'incitatif matériel à l'emploi conformément à la Règle d'Inscription Nasdaq 5635(c)(4).
Les RSU ont un calendrier d'acquisition de quatre ans, avec 25 % d'acquisition après 12 mois de service continu, suivis de versements annuels égaux sur les trois années suivantes. Cette initiative est en phase avec la stratégie de Schrödinger pour attirer et retenir les meilleurs talents dans le domaine concurrentiel de la découverte de médicaments et de matériaux computationnels.
Schrödinger (Nasdaq: SDGR), ein Unternehmen, das die Entdeckung von Therapeutika und Materialien mithilfe physikbasierter Computerplattformen revolutioniert, hat die Vergabe von Restricted Stock Units (RSUs) an 13 neue Mitarbeitende bekannt gegeben. Am 14. August 2024 verlieh das Unternehmen insgesamt 7.500 RSUs im Rahmen seines Inducement Equity Incentive Plans von 2021. Diese Zuweisungen, die vom Vergütungsausschuss genehmigt wurden, dienen als materieller Anreiz für die Beschäftigung gemäß der Nasdaq Listing Rule 5635(c)(4).
Die RSUs haben einen Vesting-Zeitplan von vier Jahren, wobei 25% nach 12 Monaten ununterbrochener Dienstzeit fällig werden und im Anschluss gleichmäßige jährliche Raten über die folgenden drei Jahre gewährt werden. Dieser Schritt entspricht der Strategie von Schrödinger, erstklassige Talente im wettbewerbsintensiven Bereich der computergestützten Arzneimittel- und Materialentdeckung anzuziehen und zu halten.
- Attracting new talent with 7,500 RSUs granted to 13 new employees
- Compliance with Nasdaq Listing Rule 5635(c)(4) for inducement grants
- Potential dilution of existing shareholders' stock value due to new RSU issuance
The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee’s completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date.
The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company’s 2021 Inducement Equity Incentive Plan.
About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The computational platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.
Founded in 1990, Schrödinger has approximately 850 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn, or visit our blog, Extrapolations.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240816145169/en/
Investor contact:
Allie Nicodemo
allie.nicodemo@schrodinger.com
Source: Schrödinger
FAQ
How many RSUs did Schrödinger (SDGR) grant to new employees on August 14, 2024?
What is the vesting schedule for the RSUs granted by Schrödinger (SDGR)?
Under which plan were the RSUs granted by Schrödinger (SDGR)?
Why did Schrödinger (SDGR) issue these RSUs to new employees?
